Shares of CryoPort, Inc. (NASDAQ:CYRX) have been assigned an average broker rating score of 1.33 (Strong Buy) from the three analysts that cover the stock, Zacks Investment Research reports. One analyst has rated the stock with a buy recommendation and two have issued a strong buy recommendation on the company. CryoPort’s rating score has declined by 33% from three months ago as a result of a number of analysts’ ratings changes.
Brokers have set a one year consensus target price of $7.50 for the company and are expecting that the company will post ($0.09) EPS for the current quarter, according to Zacks. Zacks has also assigned CryoPort an industry rank of 82 out of 265 based on the ratings given to related companies.
Several equities research analysts have recently weighed in on the company. Janney Montgomery Scott set a $8.00 price target on CryoPort and gave the company a “buy” rating in a research report on Wednesday, July 26th. Needham & Company LLC upped their price target on CryoPort from $6.00 to $8.50 and gave the company a “buy” rating in a research report on Wednesday, July 26th. Cowen and Company assumed coverage on CryoPort in a research report on Friday, June 16th. They set an “outperform” rating and a $5.50 price target on the stock. Finally, ValuEngine upgraded CryoPort from a “sell” rating to a “hold” rating in a research report on Thursday, May 11th.
Shares of CryoPort (NASDAQ:CYRX) traded down 5.88% during midday trading on Friday, reaching $6.56. 128,809 shares of the company’s stock were exchanged. The firm has a 50 day moving average price of $5.30 and a 200 day moving average price of $3.65. The company’s market cap is $157.28 million. CryoPort has a 12 month low of $1.80 and a 12 month high of $7.18.
An institutional investor recently bought a new position in CryoPort stock. Taylor Wealth Management Partners purchased a new stake in shares of CryoPort, Inc. (NASDAQ:CYRX) during the second quarter, according to its most recent Form 13F filing with the SEC. The institutional investor purchased 376,240 shares of the company’s stock, valued at approximately $1,851,000. Taylor Wealth Management Partners owned about 1.57% of CryoPort at the end of the most recent quarter. Hedge funds and other institutional investors own 10.57% of the company’s stock.
CryoPort Company Profile
Cryoport, Inc (Cryoport) is a provider of cryogenic logistics solutions to the life sciences industry through its purpose-built packaging, information technology and specialized cold chain logistics expertise. The Company provides logistics solutions for biologic materials, such as immunotherapies, stem cells, chimeric antigen receptors (CAR)-T cells, and reproductive cells for clients.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for CryoPort Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CryoPort Inc. and related companies with MarketBeat.com's FREE daily email newsletter.